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Aim: Identification of patient with increased risk of cardiotoxicity would allow not only prevention and early diagnosis of chemo-
therapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. Materials and methods: Fifty-
two women with HER2+ breast cancer treated with trastuzumab were included in this study. Patients were prospectively followed 
with routine cardiac evaluation. Before and after administration of trastuzumab blood samples for NT-proBNP were also taken. 
Results: The median age was 48.5 year (range: 26–74). Hypertension and obesity were two most common co-morbidities. The me-
dian duration application of trastuzumab was 52 weeks. During median 14.5 (3–33) months follow-up cardiac adverse events 
occurred in 5 (9.6%) patients and 2 out of 5 was grade III–IV heart failure. Both patients had preserved left ventricular ejection 
fraction and no symptom of heart failure before trastuzumab but older than 65 years old and had diabetes mellitus and obesity. High 
level of NT-proBNP (> 300 ng/ml) was observed in both patients and heart failure recovery was not observed. There was statisti-
cally significant difference regarding body mass index (p = 0.004) and diabetes mellitus (p = 0.002) between patients with and 
without cardiotoxicity. Conclusion: Although, cardiac biomarkers still cannot replace routine cardiac monitoring, natriuretic 
peptides may provide additional tool for detection of patients with high risk of cardiotoxicity and early detection of cardiotoxicity.
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Breast cancer (BC) is most common cancer and 
second leading cause of cancer death among women 
in developed countries [1]. BC is heterogeneous disease 
with different genetic and clinicopathologic features. 
Almost one-fourth of the patients show overexpression 
of human epidermal growth factor receptor 2 (HER2) [2, 
3]. Treatment targeting HER2, such as trastuzumab, has 
dramatically changed clinical course of those patients 
[4, 5]. Although, the exact mechanism is still unclear, 
trastuzumab is associated with cardiotoxicity in subset 
of patients [4–9].  According to recent Cochrane meta-
analysis, trastuzumab significantly increases the frequen-
cy of left ventricular ejection fraction decline and the risk 
of symptomatic heart failure (HF) [10, 11]. American 
College of Cardio logy Foundation/American Heart Asso-
ciation (ACCF/AHA) guidelines classify patients receiving 
cardiotoxins as stage A HF, and recommend aggressive 
control and treatment of modifiable risk factors [12]. For 
that reason, optimal cardiac management is crucial for 
both prevention and early diagnosis of chemotherapy 
related cardiotoxicity. In addition, because the optimal 
survival benefit of adjuvant trastuzumab achieved with 
one-year treatment, it is also important for optimal dose 
and duration of chemotherapy [13–15].
Clinical trials usually include selected patients who 
are usually under 65 and without serious co-morbidi-
ties. Nonetheless, the median age of patients with 
BC is over the 60, and 40% of patients are over 65, and 
20% over 75 [1, 10, 11, 16]. Older women has higher 
risk of cardiotoxicity. Therefore, clinical trials may not 
represent real world. In additionally, median survival 
of patients with BC has been improved. The estimated 
5 year overall survival is also reached to 80–85% for 
patients who were diagnosed between 1999–2005 [1, 
17]. Finally, number of cancer survivors has been 
increased and late toxicities become more important 
for those patients.
HF is a complex clinical syndrome. According 
to underlying cause, while half of patients present with 
HF with reduced ejection fraction (HFrEF), second 
half have HF with preserved ejection fraction (HF-
pEF). The diagnosis of HFpEF is more challenging. 
HFpEF are usually observed in obese older women 
with a history of hypertension, diabetes mellitus 
(DM), and hyperlipidemia [12, 18]. There is no single 
test for the diag nosis of HF but ejection fraction (EF) 
is consi dered important in classification of patients 
with HF and response to treatments. Also clinical tri-
als usually selected patients based on EF. However, 
measurement of EF is dependent operator, imaging 
technique, and method of analysis. B type natriuretic 
peptides (BNP) are secreted by ventricular cardio-
myocytes in response to increased ventricular stretch. 
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After release of propeptide (proBNP), it converts 
in to biologically inert amino terminal (NT-proBNP) 
and biologically active BNP [19]. The role of BNP and 
NT-proBNP has been well defined in diagnosis of both 
HFrEF and HFpEF [12, 20, 21]. EF alone may not pre-
dict cardioto xicity of chemotherapy for all patients and 
the optimal monitoring and treatment algorithm for 
trastuzumab related cardiotoxicity remain to be es-
tablished. The purpose of this study was to evaluate 
the role of serum biomarker in early diagnosis or pre-
diction of trastuzumab related cardiotoxicity.
MATERIALS AND METHODS
Patients. All patients with HER2-positive BC who 
were treated with trastuzumab either single-agent 
or combined with chemotherapy agents were included 
in this study. Demographic and clinical data of patients 
were reported on case record forms designed for data 
collection for this study. Patient characteristics con-
sidered relevant for cardiotoxicity were age, Eastern 
Cooperative Oncology Group (ECOG) performance 
status, prior anthracycline therapy, prior radiotherapy, 
hypertension, DM, hyperlipidemia, obesity, and renal 
failure. This study was approved by the Institutional 
Review Board of Ankara University School of Medicine 
and was conducted according to Helsinki Declaration 
and good clinical practice.
Biochemical measurements. All blood samples 
were collected after 5 min supine rest and 30 min 
before and 30 min after trastuzumab administration. 
Samples were immediately centrifuged and separated 
sera were stored at −80 °C at the hospital laboratory 
until assayed. Before assay performed all samples 
were anonymized. NT-proBNP was measured using 
the commercially available electrochemiluminescence 
immuno-assay (Roche Cobas e601, Roche Diagnos-
tics GmbH, D-68298 Mannheim, Germany). The staff 
that performed assay was masked to the patient’s di-
agnosis and cardiac status.
Cardiac tests. Routine cardiac evaluation of all 
patients was performed before trastuzumab treatment 
and follow-up echocardiography or Multiple-Gated Ac-
quisition scanning (MUGA) scan were performed every 
3 months during treatment and also in case of HF related 
symptoms. A cardiac event was defined as the deve-
lopment of symptomatic HF or more than 10% decline 
of left ventricular ejection fraction (LVEF). Grading of all 
toxicities was done according to National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(CTCAE, version 4.0, published May 28, 2009).
Statistical analysis. Statistical analysis was 
carried out using the computer program Statistical 
 Package for the Social Sciences 11.5 for Windows 
(SPSS, Inc, Chicago, IL, USA). Frequency (percent) 
or median (minimum-maximum) was given as de-
scriptive statistics. Chi-square test was used to deter-
mine differences in proportions. p Value of less than 
0.05 was considered as statistically significant.
RESULTS
The median age of patients was 48.5 year 
(range: 26–74). Hypertension and obesity were two 
most common co-morbidities. Patients’ basal and 
pre-trastuzumab characteristics were summarized 
at Table 1 and 2.
Table 1. Patients’ basal characteristics
Parameters n (%)
Age, year
Median, range 48.5 (26.0–74.0)
Menopausal status, n (%)
Pre- 26 (50.0)
Peri- 4 (7.7)
Post- 22 (42.3)
Hypertension 11 (21.2)
DM 8 (15.4)
Coronary arterial disease (CAD) 1 (1.9)
Hyperlipidemia 6 (11.5)
Smoking 5 (9.6)
Body mass index (BMI), kg/m2
Median, range 28 (18.0–41.1)
< 25 9 (17.3)
25–30 25 (48.1)
> 30 18 (34.6)
Creatinin, mg/ml 0.77 (0.36–1.0)
Glucose, mg/ml 95 (77.0–202.0)
Triglyceride, mg/ml 113.5 (44.0–256.0)
High-density lipoprotein, mg/ml 50.5 (34.0–75.0)
Uric acid, mg/ml 3.6 (2.4–6.2)
Table 2. Pretrastuzumab patients’ BC features
Features Number patientsn = 52 %
ECOG performance status
0 45 86.5
1 7 13.5
Laterality
Right 20 38.5
Left 32 61.5
Stage
Metastatic 14 26.9
Non-metastatic 38 73.1
Estrogen receptors
Positive 35 67.3
Negative 17 32.7
Progesterone receptors
Positive 40 76.9
Negative 12 23.1
HER2
İmmunohistochemistry (+3) 51 98.0
FISH/CISH 1 2.0
Pre-trastuzumab anthracycline#
No 13 25.0
Yes 39 75.0
Radiotherapy (n = 25)
Right breast 9 36.0
Left breast 16 64.0
Hormonal treatment (n = 46)
Tamoxifen 34 73.9
Aromatase inhibitor 12 26.1
#Total anthracycline dose, median (mg/m2): doxorubicin — 240, epirubicin — 
300. Time from last anthracycline administration to trastuzumab, median 
(range), month: 1 (1–110). Trastuzumab therapy duration, median (range), 
week: 52 (9–120).
The median duration of trastuzumab application 
was 52 weeks. None of patients was given concur-
rently anthracycline and trastuzumab. During median 
14.5 (3–33) months follow-up cardiac adverse events 
occurred in 5 (9.6%) patients. Grade III–IV HF ob-
served in 2 (3.8%) patients. Although both patients had 
normal EF and no symptom of HF before trastuzumab, 
high level of NT-proBNP was observed for both before 
and post trastuzumab. Asymptomatic LVEF decrease 
was observed in 3 (5.6%) patients. After discontinu-
ation of trastuzumab cardiac recovery was observed 
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in 3 patients with asymptomatic EF decrease. However, 
in 2 patients with symptomatic HF recovery was not ob-
served and both patients was older than 65 years-old 
and had DM and obesity (Table 3 and 4). Overall, there 
was statistically significant difference regarding BMI 
(p = 0.004) and DM (p = 0.002) between patients who 
have manifested and not manifested cardiac toxicity.
Table 3. Cardiac characteristics of patients
Cardiac characteristics Median (range)Pretrastuzumab Posttrastuzumab
Heart rate, per minute 78 (56—104) 76 (62–108)
EF, % 65 (55—75) 62 (40—77)
NT-proBNP level, pg/ml 50 (5—694) 49 (5—829)
CK-MB level, ng/ml 1.33 (0.49—2.82) 1.35 (0.09—3.12)
DISCUSSION
The data from this study show that, a higher level 
of NT-proBNP is associated with cardiotoxicity even 
in patients with preserved baseline LVEF. Older patients 
with high BMI and with history of DM have higher risk 
trastuzumab related cardiotoxicity. Although HF is usu-
ally reversible after discontinuation of trastuzumab and 
appropriate treatment of HF, patients with NT-proBNP 
higher than 300 pg/ml were unlikely recovered from HF.
Cancer and CAD are two leading causes of death. 
These two diseases combined accounted for ap-
proximately half of deaths in the developed countries. 
While overall CAD mortality has shown a downward 
trend, the incidence and prevalence of HF has still 
exhi bited an upward trend [22]. In the last 2 decades, 
new classes of treatment provided improvement 
in survival and have been approved for the treatment 
of various type of cancer. On the other hand, new type 
of toxicities has been also witnessed. While these 
toxicities were mostly associated with morbidity and 
affect quality of life, treatment related mortality was 
also reported [23]. In addition, these toxicities lead 
to treatment interruptions and discontinuation that 
results in inferior treatment outcome.
Cardiotoxicity is well known anthracyclines related 
toxicity and usually dose dependent, predictable, and 
irreversible. Although, it may occur during relatively 
new treatment such as trastuzumab, bevacizumab, 
and tyrosine kinase inhibitors [24–26]. The cardio-
toxicity of these drugs usually dose independent 
and reversible. Trastuzumab is a monoclonal anti-
body against HER2 receptor, which over expressed 
in 20–25% of BC. Although the exact mechanism 
is not clear yet, trastuzumab related cardiotoxicity has 
been well established in randomized clinical trials and 
meta-analysis. Age, obesity, history of heart disease 
and use of anthracyclines are known risk factors for 
trastuzumab related cardiotoxicity. Although lifetime 
risk of BC is increased with age, in our population 
we see BC at earlier age than US women. Almost half 
of patients with BC are under 50 in our country [27]. 
Likewise, median age was 48.5 years old in present 
study. However, both groups of patients with irrever-
sible HF were older than 65 years old.
In early study, Slamon et al. [5] showed the survival 
advantage of adding trastuzumab to chemotherapy 
in patients with advanced BC. However, in this study 
also carditoxicity was frequently observed. The fre-
quency of New York Heart Association (NYHA) class 
III–IV cardiac dysfunction was 27 and 13% in patients 
who were treated with anthracycline, cyclophospha-
mide plus trastuzumab and paclitaxel plus trastu-
zumab, respectively. After these results, baseline and 
follow-up cardiac monitoring were added subsequent 
trial. Despite strict inclusion criteria, carditoxicity is still 
occurred in clinical trials. According to recently pub-
lished Cochrane review, in patient with early BC, who 
has high chance of cure, trastuzumab increased risk 
of HF 5 fold and LVEF decline 2 fold [11]. Randomized 
controlled trials have generally excluded older patients 
with major comorbidities. Therefore, frequency of car-
diotoxicity is expected to be more common in the real 
world. Recently, Bowles et al. [6] reported population 
based retrospective cohort study of 12 500 women with 
BC. At median 4.4 years follow up time, the risk of HF/
cardiomyopathy was 4 to 7 fold higher in patients with 
trastuzumab alone or anthracycline plus trastuzumab. 
In addition, the risk of HF has been continued to increase 
during follow — up. In another population based study 
from Italian Cardio-Oncologic Network, trastuzumab 
cardiotoxicity rate was 27% and also treatment inter-
ruption rate was higher than clinical trials [28].
Due to, patients on chemotherapy were consi-
dered as stage A HF, patient with risk of developing 
HF, preventive intervention, early detection and treat-
ment of chemotherapy-induced cardiotoxicities are 
Table 4. Characteristics’ of 5 patients with cardiotoxicity
Clinical characteristics Patient1a 2a 3a 4b 5b
Pretrastuzumab age, years 66 72 48 52 44
Menopausal status Post- Post- Post- Pre- Pre-
Hypertension No Yes No No No
DM Yes Yes Yes Yes No
BMI, kg/m2 30.92 31.39 31.08 30.22 25.31
Total anthracycline dose, mg/m2 600 (E) No 60 (A) 240 (A) 180 (A)
Radiotherapy No No No Yes No
Chemotherapy# 6EC5TH 6TCH7H A6TH14H 4AC4TH13H 3AC3TH5H
Creatinin, mg/dl 1.0 0.97 0.8 0.55 0.73
Pretrastuzumab, EF, % 55.0 60.0 62.5 55.0 60.0
Pretrastuzumab, NT-proBNP level, pg/ml 370 694 41 49 72
Posttrastuzumab, EF, % 35 40 48 49 52
Posttrastuzumab, NT-proBNP level, pg/ml 426 829 43 44 104
Cardiac status after discontinuation of trastuzumab Symptomatic HF Symptomatic HF Recover after 
2 months EF: 65%
Recover after 
4 months EF: 55%
Recover after 
3 months EF: 60%
aMetastatic disease. bAdjuvant treatment. #Chemotherapy was administered every 3 weeks. A — adriamycine; C — cyclophosphamide; E — epirubicine; 
H — trastuzumab; T — docetaxel.
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needed for reducing severe, irreversible, late onset 
cardiotoxicity and optimal treatment of cancer. In daily 
clinical practice calculation of EF, by echocardiogra-
phy or MUGA scan, is most widely used method [29]. 
 However, because of EF does not usually decrease 
in early stage HF, EF has some limitations for early 
detection or prediction of late onset left ventricular 
dysfunction. In addition, half of patients with HF have 
HFpEF despite lower risk of death than patient with 
HFrEF, those patients mortality rate is still high [30–32]. 
As well as, echocardiography is mostly operator de-
pendent and MUGA scan causes radiation exposure. 
Therefore, non-invasive predictive and prognostic 
tests of HF for patients on chemotherapy are needed. 
The role of serum biomarker such a troponin, natriure-
tic peptides has been well established by meta-
analysis and both BNP and NT-proBNP are endorsed 
in current guidelines plus clinical evaluation [20, 
33–36]. The normal level of BNP/NT-proBNP are very 
low and increased myocardial wall stress lead to eleva-
tion of serum level [21, 34, 37]. In contrast to the echo-
cardiography and MUGA scan, HFpEF and diastolic 
HF may cause elevated BNP/NT-proBNP. However, 
not only CAD but advancing age and renal dysfunc-
tion might cause higher levels, while lower levels may 
be detected in patients with obesity and overt HF [21, 
37]. Although, adjusted cutoff values are proposed for 
renal dysfunction and obesity, <30–50 pg/ml of BNP 
and <300 pg/ml of NT-proBNP have high accuracy 
for excluding HF. In additionally, the prognostic value 
of natriuretic peptides has also been reported and 
higher values were associated with worse progno-
sis [21]. Likewise, patient without history of HF and 
with elevated natriuretic peptides levels are at higher 
risk for cardiovascular events [38]. In two recent meta-
analysis Felker et al. and Porapakkham et al. reported 
that biomarker guided treatment of HF was associated 
with 31% and 24% reduction in all causes of morta lity 
compared to routine daily practice in patients with 
HF [33, 39]. Therefore, not only for diagnosis but also 
for optimizing treatment and reduction in mortality, 
natriuretic peptides may have additional value.
This study has several limitations: our cohort 
has smaller sample size and possibly fewer events, 
so the analyses were primarily exploratory, so, no de-
finitive conclusions cannot be drawn. However, it sup-
ports of the potential clinical application of NT-proBNP 
as a predictive marker to consider cardiac manage-
ment of patients treated with trastuzumab.
In conclusion, although, cardiac biomarkers still 
cannot replace routine cardiac monitoring, natriuretic 
peptides may provide additional tool for detection 
of patients with high risk of cardiotoxicity and early 
detection of cardiotoxicity.
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